Why the study?
Consideration of patient preferences for GDMT for HFrEF may help address major gaps in prescribing and adherence, motivating the identification of factors influencing patients' decisions to take medications.
Patients with HFrEF prioritize treatment benefits (survival, quality of life) and good communication over risks, costs, and inconvenience when deciding to take medications.
Supports prioritizing survival benefits and communication in HFrEF medication counseling; extends patient-centered evidence informing guidelines.
INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing patients' decisions to take HFrEF medications. MATERIALS AND METHODS: This was a convergent mixed methods study of patients with HFrEF. Focus groups were conducted to identify a list of factors followed by individuals rating and ranking the influence of each factor on their decision to take a medication. Using thematic analysis, we summarized preferences into categories. RESULTS: Two focus groups with 13 participants reported 22 factors. Of the factors, "keeping you alive" was most commonly ranked in the top three (seven participants), followed by "communication and understanding" (six participants). Factors were summarized into six categories (listed in order of patient-reported influence): 1) demonstrated improvements in quality of life and longevity, 2) decreased risk of hospitalization, 3) opportunity for shared decision-making and trust in provider, 4) absence of adverse events, 5) affordability, and 6) convenience of taking and absence of interference with daily life. CONCLUSION: Patients prioritize treatment benefits and being informed more than risks, cost and inconvenience of taking HFrEF medications.
No takes yet. Share an insight, caveat, or question.
Trinkley et al. (2020) studied heart failure with reduced ejection fraction (HFrEF) (n=13). Patient preferences for HFrEF medications was evaluated on Factors influencing decisions to take HFrEF medications. Among 13 patients with HFrEF, 'keeping you alive' was the most commonly top-ranked factor (7 participants) influencing medication decisions, followed by 'communication and understanding' (6 participants).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: